Related Experiment Video

Updated: Aug 8, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Oncostatin M suppresses EGF-mediated protein tyrosine phosphorylation in breast cancer cells

M J Spence1, R E Vestal, Y Ma

  • 1Department of Veterans Affairs Medical Center, Boise, ID 83702, USA. myexpense@aol.com

Cytokine
|July 6, 2000
PubMed

Insights

Oncostatin M (OM) significantly suppresses epidermal growth factor (EGF)-mediated protein tyrosine phosphorylation in breast cancer cells after 72-hour treatment. This effect on EGF receptor (EGFR) signaling occurs independently of EGFR expression levels.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Signal Transduction

Background:

  • Epidermal Growth Factor (EGF) signaling pathways are crucial in cell proliferation and cancer.
  • Oncostatin M (OM) is a cytokine with complex roles in cell growth and differentiation.
  • Understanding the interplay between OM and EGF signaling is vital for breast cancer research.

Purpose of the Study:

  • To investigate the effect of Oncostatin M (OM) on epidermal growth factor (EGF)-mediated protein tyrosine phosphorylation in H3922 infiltrating ductal breast carcinoma cells.
  • To determine if OM affects EGF receptor (EGFR) expression or tyrosine phosphorylation.
  • To explore the mechanism of OM's influence on EGF signaling.

Main Methods:

  • Western blot analysis to assess protein tyrosine phosphorylation and EGFR expression.
  • Flow cytometry to verify EGFR expression.
  • Radioligand EGF binding studies to evaluate EGF receptor affinity.

Main Results:

  • 72-hour pretreatment with OM suppressed EGF-stimulated protein tyrosine phosphorylation by 77% in H3922 cells.
  • OM pretreatment suppressed EGF-mediated tyrosine phosphorylation of EGFR by 55% without reducing EGFR protein expression.
  • The suppressive effect of OM was observed even in a subclone (H3922-8) lacking high-affinity EGF receptors.

Conclusions:

  • Oncostatin M exerts a potent inhibitory effect on EGF-mediated protein tyrosine phosphorylation in breast cancer cells.
  • This suppression is not due to reduced EGFR expression or induction of protein tyrosine phosphatases.
  • OM's inhibitory mechanism on EGF signaling is complex and warrants further investigation, impacting both EGF-responsive and unresponsive cells.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...